Five independent magu^Tn10\tetR over-expression construct insertions yield increases in median life span inb oth males and females ranging from 2 to 18%. In contrast line P{tetR-magu}103 yeilded a 14% increase in median life span in males but no increase in females, while line P{tetR-magu}67-2 gave no increase in either sex.

In a Tn10\tetR^{Act5C.T:Hsim\VP16} background, two magu^Tn10\tetR lines P{tetR-magu}102 and P{tetR-magu}67-1 each give increases in median life span in both males and females, ranging fro 2.6 to 21%.

Two P{tetR-magu} insertions, P{tetR-magu}102 and P{tetR-magu}67-1, both yield increases in median life span in females of 28%, while no significant effect is found in males. In a background containing both Tn10\tetR^{M2.alt.Scer\UAS.T:Hsim\VP16} and Scer\GAL4^D42 these insertions still show an increased life span in female flies but not male flies and an increase in median life span in both males and females, ranging from 9 to 37%.

magu^Tn10\tetR overexpression (in the presence of DOX) increases female fecundity in late adult life (from day 30 to day 40), but also results in reduced female fecundity in earlier life (days 10-20). This may be due to maternal-effect lethality, in that relatively normal quantities of morphologically normal appearing eggs are laid, but the majority of these eggs fail to hatch. There may also be some dose-dependent decreases in female fecundity at both time points.

magu^Tn10\tetR overexpression mutants (under the control of Scer\GAL4^D42 and Tn10\tetR^{M2.alt.Scer\UAS.T:Hsim\VP16}), where DOX administration is initiated at age 40 days, exhibit increased female fecundity at late ages at one or more DOX concentrations. The late-age administration of drug had no negative effect on female survival.